Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | TNKS | O95271 | 6/20 | 0.51 |
| ▸ | TNKS2 | Q9H2K2 | 6/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CHKA | P35790 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11949642 | 0.88 | MAPT (0.53) | MAPTHTTLMNAPOLBTDP1 | |
| SCHEMBL11949640 | 0.88 | MAPT (0.47) | MAPTHTTPOLBTP53MEN1 | |
| SCHEMBL11949645 | 0.87 | MAPT (0.52) | MAPTHTTPOLBTDP1MEN1 | |
| SCHEMBL11949649 | 0.84 | GCK (0.56) | MAPTHTTLMNATDP1MEN1 | |
| SCHEMBL11949735 | 0.81 | SMN1; SMN2 (0.54) | MAPTHTTPOLBTDP1MEN1 | |
| SCHEMBL11949648 | 0.81 | MAPT (0.58) | MAPTHTTPOLBTDP1GAA | |
| SCHEMBL11949639 | 0.81 | RAB9A (0.50) | MAPTHTTLMNAPOLBKMT2A | |
| SCHEMBL11949637 | 0.81 | KDM4E (0.66) | MAPTHTTLMNAPOLBTP53 | |
| SCHEMBL11949650 | 0.81 | SMN1; SMN2 (0.62) | MAPTHTTLMNAPOLBTDP1 | |
| SCHEMBL11949653 | 0.81 | MAPT (0.50) | MAPTHTTLMNAPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865704-B2 | Wnt pathway antagonists | SIENA BIOTECH S.P.A. (IT) | 2014-10-21 | — | — | US | disclosed |
| US-8865704-B2 | Wnt pathway antagonists | SIENA BIOTECH S.P.A. (IT) | 2014-10-21 | — | — | US | disclosed |
| US-20120196851-A1 | WNT PATHWAY ANTAGONISTS | SIENA BIOTECH S.P.A. (IT) | 2012-08-02 | — | — | US | disclosed |
| US-20120196851-A1 | WNT PATHWAY ANTAGONISTS | SIENA BIOTECH S.P.A. (IT) | 2012-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196851-A1 | WNT PATHWAY ANTAGONISTS | WNT1, WNT3A, CTNNB1 | MAPT 4418/4885TNKS 562/4885TNKS2 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.